Background Pre-eclampsia is thought to have a polygenic basis, but the identification of susceptibility genes and the quantification of associated risks have been elusive owing to lack of replication from published genetic association studies.
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Background Pre-eclampsia is thought to have a polygenic basis, but the identification of susceptibility genes and the quantification of associated risks have been elusive owing to lack of replication from published genetic association studies.
Objective
To perform a systematic review and meta-analysis of genetic association studies to evaluate the evidence for the associations of various candidate genes with pre-eclampsia.
Methods
For inclusion, studies had to involve unrelated subjects and examine the associations between pre-eclampsia (excluding publications without a measurement of proteinuria) and any candidate variant. Authors were contacted to obtain unpublished data when necessary. A meta-analysis was conducted for all variants with three or more independent samples available. Summary odds ratios (ORs), 99% confidence intervals (CIs) and P-values were calculated using random effects models.
Results
Data from 192 genetic association studies met the selection criteria and were included in 25 independent meta-analyses. There was some evidence of association for F5 rs6025 (OR ¼ 1.74; 99% CI 1.43-2.12), F2 rs1799963 (OR ¼ 1.72; 99% CI 1.31-2.26), ACE rs4646994 (OR ¼ 1.17; 99% CI 0.99-1.40), AGT rs699 (OR ¼ 1.26; 99% CI 1.00-1.59) and AGTR1 rs5186 (OR ¼ 1.22; 99% CI 0.96-1.56), but only the first two associations reached moderate epidemiological credibility. Possible bias resulting from small study size and poor reporting of individual studies were the most important factors affecting the reported associations.
Conclusion To date, candidate gene studies in pre-eclampsia have not robustly documented any associations with strong epidemiological credibility. Large-scale replication of the most promising associations, exhibited by two genetic variants, and incorporation of agnostic high-throughput data may improve our genetic knowledge base for this complex phenotype.
Introduction
Pre-eclampsia, defined as the development of hypertension and proteinuria during pregnancy, is a major cause of death and morbidity in the mother and infant. It has an uncertain aetiology, it is difficult to predict, and no effective intervention other than delivery currently exists. Pre-eclampsia occurs in 2-8% of all pregnancies, 1,2 and along with eclampsia, which has an incidence of 0.1-0.8%, 3, 4 it has been estimated to account for 463 000 deaths worldwide each year. 5, 6 The disappointing results from recent randomized trials on primary prevention of pre-eclampsia 7, 8 have called into question the approach used to identify targets amenable to intervention. The lack of adequate animal models and the inherent biases present in observational studies that investigate the causes of pre-eclampsia, very often of small size, are other major obstacles to understanding its aetiology.
An alternative for detecting modifiable causes of pre-eclampsia while minimizing bias and confounding is the use of a genetic approach. 9 Several aspects of genetic variants, such as being randomly allocated from parents to offspring independently of other characteristics (Mendel's second law), as well as being a lifetime fixed characteristic, lead to minimized confounding and biases. 9, 10 Familial aggregation and twin studies have estimated the heritability of pre-eclampsia to be $55%, with a maternal genetic effect of 30-35% 11,12 and a contribution of fetal genes of 20%. 11 In theory, identification of candidate genes for pre-eclampsia could substantially aid the understanding of this important public health problem and provide clues for its prevention and treatment. However, individual genetic studies conducted during the past two decades using a candidate gene approach have been unable to reliably identify genetic variants involved. As for other complex diseases before genome-wide association studies (GWAS), major obstacles to the identification of genetic variants that affect pre-eclampsia risk are the likely small influence of individual genetic loci, the complex interplay between environmental exposures and polygenic susceptibility, [13] [14] [15] [16] and the lack of replication of promising results in large genetic association studies. This has led to uncertainty about the strategy conducted so far and the nature and number of genes actually contributing to pre-eclampsia risk. 15, 17 Most commonly, the identification of candidate genes and the quantification of the associated risks have involved the assessment of single nucleotide polymorphisms (SNPs) in studies including unrelated subjects. This design requires sample sizes of thousands to have adequate power to detect realistic genotypic relative risks of $1.1-1. 3 . 18 Few studies have been of this size in the pre-eclampsia field. Therefore, a comprehensive systematic review of all genetic association studies to date in pre-eclampsia was undertaken to provide quantitative summary evaluations of the cumulative evidence of the effect of genetic variants on the risk of pre-eclampsia.
Methods
Search strategy
Electronic databases (MEDLINE, EMBASE and KoreaMed) were searched using MeSH headings and text words for all genetic association studies evaluating any candidate gene and pre-eclampsia up to January 2011. Search terms are contained in Supplementary Appendix 1.
A manual search was carried out for any additional study in the references of all appropriate publications, including previous meta-analyses, and the MEDLINE option 'related articles' was used for articles considered relevant. Finally, an additional search was performed on PubMed with new medical subject heading terms for each gene polymorphism with more than three publications.
Selection criteria
Both case-control and cohort studies were included in meta-analysis if they examined the association between pre-eclampsia and any polymorphic genetic variant in the mother among unrelated women. Because there is no universal agreement on the definition of pre-eclampsia, it was expected to have a variety of diagnostic criteria across publications. For inclusion, studies had to define pre-eclampsia as elevated blood pressure accompanied with proteinuria measured with at least a semi-quantitative method. Studies that included only women with gestational hypertension without proteinuria, haemolysis, elevated liver enzymes, low platelet count or superimposed pre-eclampsia were excluded to improve phenotype homogeneity. Genotype frequencies had to be provided by case-control status for homozygous and heterozygous individuals, and especial attention was drawn to the reporting of genotyping being performed using validated methods. Studies were excluded when the minor allele frequency (MAF) in the population sample was 0%, as no measure of effect can be estimated if the risk variant is not present in the sample.
Genetic variants that are not biallelic or have a complex allelic architecture were considered for meta-analysis when reporting of genotype distributions for specific alleles was uniform among studies (e.g. APOE "/2/3/4, VNTR in intron 4 of the NOS3 gene or the HLA-G polymorphisms). Only studies published as full-length articles in peer-reviewed journals were included; there was no language restriction. Abstracts, correspondence letters and congress communications were excluded as in previous field synopses for other phenotypes. 19, 20 Where relevant information was not reported or there was doubt regarding duplicate publications, authors were contacted by e-mail or post on at least two occasions to obtain the required information (e.g. genotype frequencies) before the reference was excluded for inaccessibility of data. When genotyping data for the heterozygous group was missing and could not be obtained from the authors, publications were included in sensitivity analysis if data were available for a specific model of inheritance (e.g. dominant or recessive). If results from a publication were confirmed to have arisen from overlapping samples, or if a suspected duplication could not be ruled out, the larger sample was chosen to be included in the meta-analysis.
Data extraction
From each study, the following information was entered into databases by two authors (M.C.P. and E.S.U.) and checked by a third author (J.P.C.): genotype frequencies, name of authors, year of publication, study design, geographical location, ethnic background of participants (with the population ethnicity of the country serving as a proxy when the information was not available), mean age of participants (by case-control status), frequency of nulliparous women (by case-control status), thresholds of blood pressure and proteinuria used to define pre-eclampsia, source of control subjects, criteria used for matching control subjects to cases if matching was part of the design, genotyping method and blinding of staff to case-control status when genotyping the samples. If a study reported genotype distributions separately for more than one ethnic group, the record was entered independently for each subsample. Studies with fewer than five pre-eclampsia cases were excluded from the analysis. When a publication reported genotype frequencies stratified by pre-eclampsia severity (including eclampsia subgroups), the numbers were summed to correspond to the total sample.
Statistical analysis
A meta-analysis was performed for any genetic variant with available data from at least three independent samples. This threshold has been previously selected for meta-analysis of observational and genetic association studies. 14, 21, 22 First, crude odds ratios (OR) and standard errors were estimated for each publication using logistic regression and assigning scores (0, 1 and 2) to the different genotype groups (identifying the homozygote for the common variant as the baseline group), and using a 0.5 zero cell replacement method. The log-additive model (per-allele increase in risk) was presented as the primary measure of effect; this allowed summarizing the results of each individual study in one single statistic while avoiding falsely optimistic confidence intervals (CIs) because of an assumed model of inheritance. The only exception to this was the comparisons for the APOE gene that were carried out between "2 carriers (including "2"4 patients), "3"3 patients (reference) and "4 carriers. The distribution of SNP genotypes in the control group was tested for conformity to Hardy-Weinberg equilibrium (HWE) using a chi-squared test, with exact P-values being reported; violation of HWE was determined by a P-value <0.05.
For meta-analysis, summary ORs and 99% CIs were estimated using random effects analyses with an inverse variance-weighted method, 23, 24 given that substantial between-study heterogeneity was expected for some of the associations. In the absence of any detectable between-study heterogeneity, fixed and random effects estimates coincide. The Q test was used to test for homogeneity between studies, and the I 2 metric with a 95% CI was calculated to describe the percentage of variability in point estimates that was due to heterogeneity rather than sampling error. 25 Funnel 26 and Galbraith 27 plots were used to graphically evaluate the presence of small-study effects, and the Harbord 27 and excess significance bias 28 tests were performed to assess the presence of reporting biases.
The Venice criteria were applied as a grading system for cumulative epidemiological evidence for each genetic variant to evaluate the strength of the evidence for its association with pre-eclampsia. 29 Studies were graded in three areas: amount of evidence, replication and protection from bias, and the epidemiological credibility for each meta-analysis was assessed to be strong if the association received three A grades, moderate if it received at least one B but no C grades and weak if it received at least one C grade. The amount of evidence was evaluated by the total number of minor allele copies for each variant, given that summary ORs were estimated using an additive model of inheritance. The grade was A if the total minor allele copies were 41000; it was B if the number was between 100 and 1000; it was C if the total number was <100. Replication was graded as A in two situations: if the P-value for the summary OR was 40.01 and the I 2 estimate was <25%, or if the P-value was 41 Â 10 À7 regardless of I 2 ; it was graded as B, if the P-value was 40.01 but I 2 was 425% and <50%; it was graded as C, if the P-value was 40.01 or if I 2 was 450%. 30 Protection from bias included the evaluation of the methods used for genotyping and the potential for publication and other selective reporting biases. Grade C was given to meta-analyses with a small OR (OR < 1.15) that could be easily susceptible to even minor biases, or when there were suggestions of small-study effects from the Harbord test, excess significance bias, P40.01 with the exclusion of studies with significant deviation from HWE or P40.01 with the exclusion of the first published study on the association; grade B was given if the meta-analysis had a summary OR41.15 without suggestion of bias by any of the four checks previously mentioned, but reporting of genotyping methods and quality control (QC) was not uniform across studies; grade A was given if the summary OR was 41.15, and none of the aforementioned problems existed, plus the reporting of genotyping and QC was deemed to be adequate.
Secondary analyses were conducted using fixed effects regression methods and recessive, dominant and pair-wise genotype comparisons. The parameter lambda (), a ratio of the pair-wise log ORs obtained with bivariate methods, was computed to help suggest a genetic mode of action: the model is approximately
31,32
Subgroup analyses were conducted to investigate the consistency of the overall measure of association among predefined categories of study characteristics such as the study design (case-control, prospective), the number of cases included in the study (<100, 100-500, 4500 participants), study location (Europe, North America, other), blinded genotyping (yes, no, unknown) and ethnicity of participants (Caucasian, Asian, African Caribbean, Latin American, others). Results were also stratified according to the severity of pre-eclampsia cases (mild and severe, with severe cases including those women with eclampsia). Subgroup estimates were compared with the chi-squared heterogeneity test, and sources of heterogeneity were further explored using meta-regression methods 33 for variants with 41000 cases. Sensitivity analyses were reported after excluding the discovery report and after removing studies with evidence of deviation from HWE.
Data were analysed using Stata 11.0 (Stata Corporation, College Station, TX, 2007). All P-values are two-sided. Reporting of results followed previously published recommendations. 34, 35 Definition of severe pre-eclampsia for subgroup analyses included cases with blood pressure 5160/110 mmHg, proteinuria 55 g/24 h (or dipstick 3þ) or presence of eclampsia. Fetal growth restriction was not included as a factor.
Results
Genetic association studies in pre-eclampsia Since 1990, the earliest report, the number of publications on genetic association studies in pre-eclampsia has increased rapidly, especially in the past decade. However, there has been no clear variation in the average sample size of the studies, with most of them including <200 participants (Figure 1 ). Only two studies included 4500 cases.
In total, 182 genetic variants located in 145 genes were identified as having been assessed for an association with pre-eclampsia, with an average of two studies per variant and a median of 100 cases and 115 control subjects per study. The largest proportion of studies has been conducted in Caucasian populations (57.6%), followed by studies including Asian participants (25.3%); see Supplementary Figure S1 (available as Supplementary data at IJE online) for additional details on other ethnic groups. No GWAS were identified during the searches.
Eligible studies for meta-analysis
From a total of 2684 citations retrieved in the primary search, 2187 records were reviewed by title or abstract after duplicates were removed; 1714 records did not fulfil the inclusion criteria, leaving 473 potentially relevant studies that were reviewed in full-text. A total of 192 independent publications evaluating the effect of 25 different genetic variants on pre-eclampsia were eventually included in one or more meta-analyses (Supplementary Table S4 , available as Supplementary data at IJE online). Reasons for the exclusion of the remaining 281 citations are described in Supplementary Figure S2 (available as Supplementary data at IJE online). Out of the 25 variants meta-analysed, 11 were SNPs with an amino-acid change, three were variants with an insertion/deletion, there were two variable repeats and the rest were variants located in promoters or non-coding regions of the genes; further genetic details are reported in Supplementary Table S1 (available as Supplementary data at IJE online).
Completeness and quality of the data
The accuracy of reporting was evaluated by quantifying the proportion of studies that provided information on characteristics with the potential to introduce bias to a meta-analysis (Figure 2 ). Phenotypic information was consistently reported across studies (480% for all characteristics), compared with basic demographic data about the participants that was present in 50-60% of the publications. Information concerning the genotyping method used was described in 100% of the studies, but other important procedures that assure QC of the samples was reported for 440% of the publications.
Meta-analyses of candidate-gene variants
Summary ORs estimated using random-effects models with an additive model are shown in Table 1 along   GENETIC ASSOCIATION STUDIES IN PRE-ECLAMPSIA with heterogeneity assessment for the 25 genetic variants evaluated. Overall, the genetic variants showed modest effects on pre-eclampsia with summary ORs ranging from 0.71 to 1.74. Five of the meta-analysed variants had summary ORs with P < 0.05, but only two of these associations were considered to have moderate epidemiological credibility, with the remaining three being assessed as having weak cumulative evidence. Additional information on secondary analyses using fixed-effects models and other models of inheritance are outlined in Supplementary Table S2 (available as Supplementary data at IJE online).
F5 rs6025 (Factor V Leiden) was evaluated in 49 studies, of which 85% were case-control studies, assessed the potential for publication and other selective biases taking into account the magnitude of the summary OR, the OR after exclusion of first study, the OR after exclusion of HWE-deviating studies, Harbord test and excess-significance test, as well as the evaluation of the quality of reported data with especial attention to the description of laboratory methods. Figure S5. 1, available as Supplementary data at IJE online). The MAF in the control group for the 41 samples analysed ranged from 0.3% to 7.6% (Supplementary Figure 6 .1, available as Supplementary data at IJE online), with four studies having a MAF45% (three from Sweden and one from Australia). All studies conformed to HWE assumptions. Carriers of the F5 rs6025 polymorphism seemed to have a 74% increased risk of developing pre-eclampsia (99% CI 43-112) with a P-value for the summary OR of 2.7 Â 10 À13 (Supplementary Figure S3. 1, available as Supplementary data at IJE online). There was small heterogeneity estimated by the I 2 (0%; 95% CI 0-36). The P-value for the Harbord test was equal to 0.10, suggesting a low probability of small-study effects (Supplementary Figure S4 .1a and b, available as Supplementary data at IJE online), and the test for excess of significant studies gave a P-value of 0.96. Cumulative epidemiological evidence was assessed as moderate, given the lack of standard reporting of study characteristics that may introduce bias (mainly QC laboratory methods), and the possibility of reporting biases that could not be reliably ruled out. Subgroup analysis did not reveal major differences in the effect estimates for the different categories ( Figure 3) . The effect on pre-eclampsia was stronger but not statistically different (P ¼ 0.53) among severe cases (OR 1.83, 99% CI 1.21-2.74) compared with mild cases (OR 1.57, 99% CI 1.23-2.00). Summary results and between-study heterogeneity were consistent across different models of inheritance (Supplementary Table S2 , available as Supplementary data at IJE online). Nevertheless, when using a different genetic model of inheritance (dominant), there was a suggestion for effect modification by study design (P-value for heterogeneity equal to 0.01 for chi-squared test). Sensitivity analyses with the addition of nine studies with genotype information for a dominant model of inheritance (including two cohorts from Australia and the USA) gave similar results.
A total of 32 studies evaluated the prothrombin (F2) rs1799963 variant of which 82% were case-control studies, and above half of them recruited Caucasian women (65.5%). Of the total, two publications were excluded from the meta-analysis because they did not identify the variant among cases or control subjects; for another two, the minor allele was absent in the control group, and departures from HWE could not be tested. The MAF ranged from 0% to 3.4% (Supplementary Figure S6 .2, available as Supplementary data at IJE online), and two studies violated HWE assumptions (see Supplementary Appendix 2) . Only four studies clearly stated that genotyping was blinded to the clinical status of the participants (although the information was known for a total of 11 studies after communication with authors); other QC methods were reported only by $20% of the publications (Supplementary Figure S5. 2, available as Supplementary data at IJE online).
The meta-analysis for F2 rs1799963 included 30 studies, 3546 cases, and 11 712 control subjects. The summary OR was 1.72 (99% CI 1.31-2.26), with a P-value equal to 3.2 Â 10 À7 (Supplementary Figure  S3. 2, available as Supplementary data at IJE online). The heterogeneity was small, with I 2 equal to 0% (95% CI 0-41). There was no evidence of an excess of significant studies (P ¼ 0.11). The cumulative evidence for this variant was assessed as moderate because of the total number of allele copies being <1000 and the lack of standard reporting of study characteristics that may bias the estimated summary effect. Although no difference was observed between studies with <100 or 100-500 cases, the only study that included 4500 cases estimated a larger effect (Figure 3 ), explaining the P-value of 0.018 in the Harbord regression test (Supplementary Figure S4 .2a and b, available as Supplementary data at IJE online); meta-regression identified the number of cases per study as an important source of variation (P ¼ 0.005). The effect on pre-eclampsia was also stronger among severe cases (OR 2.08, 99% CI 1.28-3.37) compared with mild cases (OR 1.60, 99%CI 1.16-2.22), but this was not statistically different (P ¼ 0.38). Sensitivity analyses excluding the study with the largest sample size retained the significance of the association (OR 1.55, 99% CI 1.13-2.11). Analyses with the addition of two studies with genotype information for a dominant model of inheritance showed no inconsistencies in the results.
The evidence for the effect of ACE rs4646994 on the risk of pre-eclampsia (OR 1.17, 99% CI 0.99-1.40) was regarded as weak because of substantial heterogeneity (I 2 of 68%) and the potential for small-study effects (Harbord P-value of 0.05). For the AGT rs699 variant (OR 1.26, 99%CI [1.00, 1.59]), the amount of epidemiological evidence was considered weak, given the unexplained substantial inter-study heterogeneity (I 2 of 70%). For AGTR1 rs5186 (OR 1.22, 99% CI 0.96-1.56), the cumulative epidemiological evidence was assessed as weak because the association lost significance once the first study was removed (P-value for the summary OR equal to 0.08). Figure 3 Subgroup estimates (99% CI) for the association with pre-eclampsia for genetic variants with nominally significant overall results. Estimations come from random-effects meta-analysis using an additive model of inheritance. N, number of studies within each subgroup; P-het, P-value for Q test of homogeneity between subgroups
The possible variation in the estimated associations among different populations was evaluated by subgroup analyses. Out of the five genetic variants with evidence of association with pre-eclampsia, only AGTR1 rs5186 showed subgroup differences (Figure 3) , with the only study conducted in African Caribbean populations estimating a protective effect compared with an increased risk for the variant in Caucasian and Asian populations. In that study, MAF was 0.0% among cases. Further replication in larger collections is needed to confirm or refute this potential differential effect by ethnic group.
The effects of the remaining associations are described in Table 1 . Three out of the 20 meta-analyses showed evidence of small-study effects (MTHFR rs1801133, EPHX1 rs2234922 and THBD C1418T), and five of them had a positive test for excess of studies with statistically significant results (MTHFR rs1801133, NOS3 rs1799983, NOS3 4a/4b, IL-10 rs1800896 and LEP TTTC). Details of the application of the Venice criteria for all variants are presented in Supplementary Table S3 (available as Supplementary data at IJE online). Among the non-significant associations, MTHFR rs1801133 and NOS3 rs1799983 accumulated a considerably large amount of evidence as judged by the number of cases (5160 and 2141, respectively, both with total minor allele copies 42000), but their estimated effect on pre-eclampsia risk was not statistically significant, and both showed evidence of reporting biases.
Discussion
This field synopsis offers the most comprehensive assessment of the genetic determinants in pre-eclampsia to date, and includes information on 25 genetic variants derived from 192 studies (30 919 cases and 69 528 control subjects) published in the past two decades. The meta-analysed variants were involved in diverse biological pathways, including lipid metabolism, vascular tone, blood pressure regulation, immune response, coagulation, angiogenesis and other metabolic pathways. Results from this overview provided an indication of five variants being potentially associated with the risk of pre-eclampsia, the most robust results seen for F5 rs6025 and F2 rs1799963. However, as with other complex diseases, 21, 36 most of the genetic signals investigated to date were not replicated by meta-analysis, and none of the variants with evidence of an association in meta-analysis had strong epidemiological credibility.
F5 rs6025 and F2 rs1799963 are two prothrombotic variants that, along with other genetic thrombophilias, have been widely studied as possible genetic causes of pre-eclampsia 37, 38 and other pregnancy complications. 39, 40 It has been hypothesized that thrombophilias cause placental vascular thrombosis and increase the risk of placental insufficiency 41 ; nevertheless, current data are insufficient to confirm their causal involvement in pre-eclampsia. 42 The meta-analysis for F5 rs6025, which included thousands of more cases than any single report 43 or previous meta-analysis, [44] [45] [46] showed an increased risk of pre-eclampsia (OR 1.74, 99% CI 1.43-2.12) with moderate cumulative epidemiological evidence. The present report did not identify effect modification by study design (prospective studies vs case-control) on the effect of the F5 rs6025 on pre-eclampsia when using an additive model (P ¼ 0.10; Figure 3) . But, as observed in a previous review, 45 there was potential effect modification by study design when using a dominant model of inheritance, with a trend for case-control studies to report a larger effect than cohort studies. Although F5 rs6025 is a variant that exhibits incomplete dominance, the dominant model has been previously preferred for the analysis of its effect owing to its low MAF. In this meta-analysis, the value of for F5 rs6025 was 0.63 (95% CI 0.18-1.08, see Supplementary Table S2 , available as Supplementary data at IJE online), suggesting that the additive (co-dominant) model is an adequate fit. Common sources of bias that often affect case-control studies, such as reverse causation, are less likely to operate in candidate gene studies, as genetic variants are non-modifiable traits allocated at birth. The main reasons for such an apparent discrepancy by study design could be mainly owing to the limited power to detect a small-to-moderate effect in prospective studies in contrast to case-control studies (820 cases from cohorts vs 3679 cases from case-control studies) (Figure 3) . Although, the present meta-analysis on F5 rs6025 did not provide evidence of small-study effects, replication of the signal detected here in large genetic studies (ideally with 41000 cases) would be valuable to increase the epidemiological credibility for this association.
The meta-analysis on the F2 rs1799963 variant showed an increased risk of pre-eclampsia with OR of 1.80 (99% CI 1.35-2.41) and a P-value in the order of 10 À7 . However, given the low MAF of this variant (<5% in Caucasians and practically non-existent among Asian and other non-Caucasian populations 47 ), this meta-analysis, the largest conducted to date, only included a total of 519 minor allele copies. This indicates that the amount of cumulative evidence for this variant is limited, and that further replication in large-scale (and high-quality) studies is needed to increase (or decrease) the credibility on this association.
It should therefore be stressed that a causal association between F5 rs6025 or F2 rs1799963 and pre-eclampsia cannot be confirmed or refuted with the available data.
For the rest of the meta-analyses in this study, limitations to the interpretation of results are mainly a consequence of the potential for bias related not only to the possibility of an excess of small, probably false-positive studies being published, but also to an overall lack of quality of reporting in the individual publications. Further updates of this field synopsis will not only serve to include new candidate variants recently investigated in pre-eclampsia (published after our search deadline) but also to explore the potential for gene-environment interactions with established risk factors for pre-eclampsia, although improvement in the quality of reporting of genetic studies is needed before embarking in such experiments.
In the future, the creation and updating of wed-based data collections for positive and negative studies, as done for other diseases (e.g. www.alzgege. org, www.szgene.com), and a continuous reporting and appraisal of genetic association studies following guidelines currently available 29, 34 would help to improve the cumulative evidence for genetic associations in pre-eclampsia. The creation of a large consortium of investigators in pre-eclampsia genetics may help alleviate much of the problem of publication bias; an emerging example of this is the InterPregGen consortium that brings together expertise on genetics of pre-eclampsia from Central Asian and European populations. 48 The studies included in our analyses focused on a limited number of candidate genes, and most of them were individually underpowered to confirm or refute realistic genotypic risks. Nevertheless, the absence of strong evidence of association for a genetic variant could also be related to a lack of biological effect. Candidate genes in pre-eclampsia research have been usually chosen because they have been previously described as putative risk factors for cardiovascular disease. These two complex diseases share many risk factors, and pre-eclampsia has been shown to increase the risk of cardiovascular disease in later life. 49 However, this strategy of restricting the investigation of pre-eclampsia genetic causes to cardiovascular disease-related genes has left unexplored, until recently, the role of genetic determinants for important targets such as angiogenic or immunological factors that have emerged as potentially causally involved. 50, 51 Furthermore, the appropriateness of the analysis of a single candidate gene/variant is directly reflected in the prior evidence of the involvement of that particular variant in the outcome development, with such evidence being limited in the case of pre-eclampsia. It is also true that pre-eclampsia is a complex disease with great phenotypic diversity, thus reaching common agreements between investigators on the definition and reporting of pre-eclampsia and in particular of the diverse sub-phenotypes of pre-eclampsia severity will contribute to a more efficient translation of future knowledge into public health and medical interventions.
Most of the published studies in pre-eclampsia have been performed in developed countries. The frequency of pre-eclampsia and its severity and complications largely vary between low-, middle-and high-income countries.
1 High-income countries have lower pre-eclampsia incidence and frequency of complications, and it is in low-and middle-income settings that the burden of the disease is more important, and the potential for intervention is greater. Whether this is due to genetic susceptibility or differential environmental exposure remains unknown. Results from ongoing GWAS from large studies conducted in a middle-income country such as the GenPE study (http://www.genpe.org) and from a high-income setting such as GOPEC 52 will allow us to evaluate this hypothesis, as well as to provide evidence of the existence of genetic determinants of pre-eclampsia that could be used to understand mechanisms of action and to propose preventive measures.
